New York, NY (PRWEB) March 10, 2015
Spheryx, Inc. will present at two upcoming meetings, the PittCon 2015 Conference and Expo, the world’s largest annual premier conference and exposition on laboratory science, and the 249th American Chemical Society National Meeting and Exposition. The presentations will cover Spheryx’s technology for Total Holographic Characterization™ based on holographic video microscopy developed in the laboratory of Prof. David Grier, Professor of Physics at New York University, Director of NYU's Center for Soft Matter Research, and co-founder of Spheryx. The authors of the presentations are Spheryx President, CEO and co-founder, Dr. Laura Philips, Dr. David Grier and Dr. Fook Cheong, also a co-founder of Spheryx. Dr. Philips will be making the presentation.
The presentation at PittCon will take place at 1 pm on March 11, in Hall F of the Ernest N. Morial Convention Center, New Orleans, LA. The presentation at the National American Chemical Society meeting will take place at 6 pm on Sunday, March 22, in Hall E, and at 8 pm on Monday, March 23, in Hall C of the Colorado Convention Center, Denver, CO.
About Spheryx, Inc.
Spheryx, Inc. is a privately held analytical services and instruments company providing Total Holographic CharacterizationTM of colloidal materials. The breakthrough proprietary technology uses holographic video microscopy to characterize each particle in colloidal dispersions and multi-component colloidal mixtures, thereby offering unprecedented insights into these materials’ characteristics. Applications include research and development, quality assurance and manufacturing process control across a broad spectrum of industries, where characterization of colloids can enhance innovation, improve safety and reduce costs. For more information please visit the company’s website at http://www.spheryx.solutions
Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or result to differ materially. These risks and uncertainties include, among others: the results, timing and costs of our studies; our ability to obtain future funding on acceptable terms; the possible impairment of, or inability to obtain intellectual property rights; and innovation by our competitors.